Beperminogene perplasmid for the treatment of critical limb ischemia. (October 2014)

• Record Type: Journal Article
• Authors: Suda, Hiroyuki; Murakami, Akihiko; Kaga, Toshihiro; Tomioka, Hideki; Morishita, Ryuichi
• Is Part Of: Expert review of cardiovascular therapy. Volume 12:Number 10(2014)
• Page Start: 1145
• Page End: 1156
• Publication Date: 2014-10
• Subjects: Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/14779072.2014.955850
• Languages: English
• ISSNs: 1477-9072

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Therapeutic angiogenesis for the treatment of ischemic disease can be attained through the delivery of recombinant growth factor proteins, through gene transfer or cell transplantation. Gene transfer associated with adenovirus or naked plasmid DNAs has been extensively studied in clinical trials. An investigational product, beperminogene perplasmid, is the naked plasmid DNA encoding the cDNA of human HGF, which has potent angiogenic activity. In several clinical trials, beperminogene perplasmid showed favorable safety and efficacy profile in the treatment of critical limb ischemia. This article reviews the results of pre-clinical and clinical studies of beperminogene perplasmid in the treatment of critical limb ischemia caused by peripheral arterial disease and Buerger's disease.</p> </abstract>